PD29-01 THE HEMATURIA CANCER RISK SCORE: A VALIDATION STUDY DEMONSTRATING REDUCTION IN THE NUMBER NEEDED TO INVESTIGATE WHILE PRESERVING FIDELITY OF CANCER DETECTION
Wei Shen Tan, John Kelly, Ashish M. Kamat(The University of Texas MD Anderson Cancer Center), Dimitrios Volanis, Arjun Nathan(British Association of Urological Surgeons), Amar Ahmad(Cancer Research UK), Wei Phin Tan(Wuhan University), Ayodeji Ogunbo, Daniel Cohen(Fondation Jean Dausset-CEPH), Olayinka Gbolahan, Neha Kallam
Cited by 0
Related Papers
A Comprehensive Human Linkage Map with Centimorgan Density
|Science|1994|537
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study
|The Lancet Oncology|2021|532
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial
|The Lancet Oncology|2020|459
Cancer incidence in the United Kingdom: projections to the year 2030
|British Journal of Cancer|2011|285
Trends in the lifetime risk of developing cancer in Great Britain: comparison of risk for those born from 1930 to 1960
|British Journal of Cancer|2015|275